https://www.selleckchem.com/pr....oducts/ag-221-enasid
The examination revealed a mutation ofASXL1. Interferon alfa therapy is carried out, against the background of which clinico-hematological remission has been achieved. Despite the identified mutation, the patient is not a candidate for allogeneic hematopoietic stem cell transplantation. Given the unfavorable prognostic value of theASXL1mutation, the patient is subject to active dynamic observation and aggressive therapeutic tactics when signs of disease progression appear.Therapy with tyrosine kinase inhibitors (TKI) allows to
Like
Comment
Share
